Sexual intimacy cures have been pedalled for centuries but science is now in the marketplace with, among others, Futura Medical's (LON:FUM) MED2002 gel getting noticed in all the right places.The publication, The Journal of Sexual Medicine, is a bit late to the party given that the headline results were announced back in September 2016 but Futura said it nonetheless shows the growing “level of scientific interest” in the gel. CEO James Barder tells Proactive why he thinks MED2002 is superior to the two other main orally-taken competitors. James also updates us on the company's Clinical Development programme and progressing their Phase III pathway through 2018.
Rep Boost for Futura Medical's Erectile Dysfunction gel
Quick facts: Futura Medical PLC
Price: 19.25 GBX
Market Cap: £47.28 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE